Considering its immunostimulatory properties and the outcomes obtained from both pre-clinical and clinical studies, the emergence of IL-24 as a potent tumor-inhibiting agent is undeniable, however, the clinical usage of this agent is practically limited by the deficiencies of targeted and efficient delivery systems (6, 72). Here, IL24 is linked to neoplasm.